| Document |
Document Title |
|
JP4856809B2 |
An dermatological agent for external use is disclosed which contains a chromanol glycoside represented by the following general formula (1) (wherein R<1>, R<2>, R<3>, and R<4>, which may be the same or different, each represent a hydroge...
|
|
JP4850302B1 |
The present invention aims to provide a particulate composition containing anhydrous crystalline 2-O- ± -D-glucosyl-L-ascorbic acid having a significantly, hardly solidifiable property compared to conventional ones in a grade for use in...
|
|
JP4851094B2 |
What is described are a compound of the formula wherein n is 0 or 1; A-B is —CH═CH— or —CH2—CH2—; R1 is C1-C12-alkyl, C3-C8-cycloalkyl or C2-C12-alkenyl; R2 is for example C1-C12-alkyl, C2-C12-alkenyl or C2-C12-alkinyl; which...
|
|
JP4846758B2 |
|
|
JP4836961B2 |
An expression inhibitor of a nuclear transcription factor AP-1 is provided that is excellent in safety and activity of inhibiting the expression of a nuclear transcription factor AP-1. The AP-1 expression inhibitor of the present inventi...
|
|
JP4836783B2 |
It is intended to provide an antitumor agent, which has established a strengthened function selectivity of acting exclusively on caner cells, lessened side effects, mastery of drug tolerance and so on, and has an activity of inducing cel...
|
|
JP4832645B2 |
Avermectin derivatives having antiparasitic activity represented by the general formula (I) or salts thereof: wherein -X ---- Y- represents -CH=CH-, -CH 2 -C(=O)-, -CH 2 -CH 2 -, or -CH 2 CH(R 13 )-; the line ---- between R 1 and the car...
|
|
JP2011529076A |
The present invention provides a method for preparing DMF for sucralose production, including, e.g., isolating DMF from a composition comprising DMF, water, and methanol, using a single-tower rectification system. In various embodiments ...
|
|
JP4826740B2 |
A flavonoid solubilization agent capable of highly solubilizing flavonoids such as isoflavone, baicalin, rutin and naringin whose solubility is generally low; and a method of effecting the above solubilization. Flavonoids can be solubili...
|
|
JP4823900B2 |
The invention relates to the use of Aivlosin for the treatment, prevention or control of diseases due to Brachyspira pilosicoli in pigs and Ornithobacterium rhinotrachelae in poultry.
|
|
JP4809611B2 |
|
|
JP4813652B2 |
|
|
JP2011527709A |
The present invention relates to a method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject. The present invention also relates to a method for treating chronic posterior blepharitis in a subject for ov...
|
|
JP4806193B2 |
Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof The invention relates to substituted heterocyclic fluoroglycoside derivatives of the formula I in which the radicals have the sta...
|
|
JP4804702B2 |
Parenteral compositions of oil-coated-Amphotericin B in structured-emulsion form, having LD50 of at least 400 mg/kg in mice and process for making the same have been described. The process essentially requires dispersing Amphotericin B i...
|
|
JP4806192B2 |
Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof. The invention relates to substituted aromatic fluoroglycoside derivatives of the formula I in which the radicals have the stated mea...
|
|
JP4805309B2 |
PCT No. PCT/EP94/00575 Sec. 371 Date Oct. 3, 1995 Sec. 102(e) Date Oct. 3, 1995 PCT Filed Feb. 28, 1994 PCT Pub. No. WO94/20627 PCT Pub. Date Sep. 15, 1994The present invention provides a method for identifying or selecting from a popula...
|
|
JP2011527292A |
The present invention relates to a macrolide derivative as well as preparation and use thereof. The macrolide derivative of the present invention, i.e., a hydrate of erythromycin salts, has a molecular formula of C 37 H 67 NO 13 ·A·nH ...
|
|
JP4801307B2 |
The invention relates to a compound of formula (I) wherein R1 is a sugar; R2 is -CH2-O-(R7)m, R7 representing a sugar, or R2 is -COOH; R3 is an epoxide-comprising group, C1-C6-alkyl or C2-C6-alkenyl, unsubstituted or substituted by at le...
|
|
JP2011207899A |
To provide the most stable crystalline form of 4"-deoxy-4"-epi-methlamino avermectin B1a/B1b benzoic acid salt from four crystalline forms of that salt which is an agricultural insecticide, and to provide a process for preparing the same...
|
|
JP4795589B2 |
In one aspect, the invention relates to a process for preparing 6-O-substituted erythromycin derivatives comprising reacting 2'-substituted and optionally 4''-substituted 9-oxime erythromycin derivatives with an alkylating agent in the p...
|
|
JP4796300B2 |
Motilide compounds having the formula (I), wherein R1, R2, R3, and R4 are as defined herein, and methods for their preparation and use in the treatment of diseases or conditions characterized by impaired gastric motility.
|
|
JP2011201871A |
To provide a process for producing a compound useful as a prophylactic or therapeutic medicine for diseases caused by hyperglycemia such as diabetes, diabetes complications and obesity, intermediates for producing the compound, and an in...
|
|
JP2011201833A |
To provide an ilidoid compound excellent in antioxidation activity.This ilidoid compound is characterized by being expressed with formula (I). Also, the antioxidant consisting of the ilidoid compound is provided.
|
|
JP4792534B1 |
The present invention aims to provide a particulate composition containing anhydrous crystalline 2-O- ± -D-glucosyl-L-ascorbic acid having a significantly, hardly solidifiable property compared to conventional ones in a grade for use in...
|
|
JP4790263B2 |
The present invention relates (a) to new compounds represented by Formula I: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, S represents a...
|
|
JP4787752B2 |
Novel isolated and purified withanamides and withanolides are described. In particular, compounds from Withania somnifera fruit are the preferred source of the withanamides and withanolides, although they can be from other plant sources....
|
|
JP2011190183A |
To provide a fluorous sugar-bonded crown ether derivative having an anomer carbon atom of a hemiketal structure as a cyclic carbon atom of the crown ether, where a hydroxy group of the sugar molecule is bonded to a fluorous tag, a fluoro...
|
|
JP4782104B2 |
The present invention relates to a pectin derived from an acerola fruit or a hydrolysate thereof, comprising a complex formed of Aceronidin, which is a novel polyphenol compound. The pectin of the present invention can be used as an acti...
|
|
JP4783633B2 |
A problem of the present invention is to provide an economical process with minimized toxicity for producing an aromatic compound having a variety of substituents such as various alkyl groups, and the problem is solved by a process for p...
|
|
JPWO2009139181A1 |
10a represented by formula (I) having a novel structure effective against Haemophilus influenzae or erythromycin-resistant bacteria (for example, resistant Streptococcus pneumoniae and streptococcus) and 10a-azalide having a 4-membered r...
|
|
JP2011178728A |
To provide a drug that is harmless to human bodies and is capable of obtaining AMPK- and GLUT4-activating effects without inducing any adverse effects, and a pharmaceutical drug, food and drink expected to be effective in improving diabe...
|
|
JP4765032B2 |
The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in Saccharopolyspora spinosa to produce the spinosyns, and methods of controlling insects using the spinosyns.
|
|
JP4768132B2 |
A synthesis of [2.2.1]bicyclo nucleosides which is shorter and provides higher overall yields proceeds via the key intermediate of the general formula III, wherein R4 and R5 are, for instance, sulfonates and R7 is, for instance, a haloge...
|
|
JP4762973B2 |
In preparing a glycoside compound from (a) a furanose compound or pyranose compound, and (b) an alcohol compound, a process for preparing a glycoside compound in which glycosidic bond locates selectively trans form relative to C-2 hydrox...
|
|
JP4758964B2 |
The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represente...
|
|
JP4755248B2 |
Seven novel antibiotic substances could be produced by cultivation of a microbial strain which has been isolated from a soil sample and which is designated as Microbispora sp. A 34030 (deposited under an access number FERM BP-10505 in te...
|
|
JP4753716B2 |
The present invention provides fused heterocyclic derivatives represented by the general formula: wherein R 1 represents H, halogen, OH, etc.; R 2 represents H, halogen or an alkyl group; R 3 and R 4 represent H, OH, halogen, etc.; Q rep...
|
|
JP2011157375A |
To provide derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)e
thyl]-2,2-diphenylacetamide having a covalently bonded acid.There are provided the derivatives and salts, solvates, and prodrugs thereof, the use of t...
|
|
JP4750755B2 |
Erythromycin derivs. of formula (I) and their acid addn. salts, are new. R = -(CH2)nAr; n = 3 - 5; Ar = heterocyclic gp. (opt. substd. one or more times) (37 gps shown in specification); or R = a gp. (i); Z = H or an acid residue. Ar can...
|
|
JP4750698B2 |
A compound of formula (I) wherein the bond between carbon atoms 22 and 23 may be a single or a double bond; R1 is C1-C12alkyl, C3-C8cycloalkyl, or C2-C12alkenyl; R2 and R3 are, for example, independently of each other hydrogen, C1-C12alk...
|
|
JP2011147446A |
To provide macrolide compounds, and the process for preparing and isolating the same, particularly the compounds which differ from natural compounds at least in terms of glycosylation.The method includes: a gene cassette containing a com...
|
|
JP4737495B2 |
|
|
JP4727990B2 |
Hydrobromide salt of morphine-6-beta-D-glucuronide (M6G.HBr), a medicament, and a pharmaceutical composition comprising the M6G.HBr are disclosed. Methods of treating diseases using M6G.HBr, use of M6G.HBr as a medicament, in particular ...
|
|
JP4724337B2 |
The invention relates to a process for preparing carbonate and carbamate compounds, which are important intermediates in the synthesis of 6-O-substituted macrolide antibiotics. The process employs metal-catalyzed coupling reactions to pr...
|
|
JP4724118B2 |
The invention relates to novel 5-thioxylose compounds, preferably derivatives of the 5-thioxylopyranose type, to the method for their preparation and to their use as active principles of drugs intended especially for the treatment or pre...
|
|
JP4717811B2 |
A compound of the formula: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally su...
|
|
JP4717163B2 |
The compounds of the present invention are prepared directly or indirectly by modifying the compounds that are naturally produced from Saccharopolyspora spinosa. The compounds of the invention have been shown to have activity against ins...
|
|
JP2011518799A |
Novel 2′-O,3′-N-bridged macrolides useful in treatment of inflammatory diseases. More particularly, the invention relates to 2′-O,3′-N-bridged 14-membered macrolides and to 2′-O,3′-N-bridged 15-membered azalide macrolides use...
|
|
JP2011126894A |
To provide azithromycin having a stable monohydrate form and a method for preparing azithromycin in the form of e.g. a stable monohydrate.The preparation method comprises (i) a step of treating azithromycin with hydrogen boride, (ii) a s...
|
